Immunocore Holdings (IMCR) Free Cash Flow (2023 - 2026)

Immunocore Holdings has disclosed Free Cash Flow across 4 years of filings, most recently posting -$15.6 million for Q1 2026.

• Free Cash Flow for Q1 2026 came in at -$15.6 million, down 11454.74% year-over-year; the trailing twelve-month figure through Mar 2026 was -$30.7 million (down 218.06% YoY), and the FY2025 annual result was -$15.1 million, down 172.06% from the prior year.
• Free Cash Flow came in at -$15.6 million for Q1 2026 at Immunocore Holdings, up from -$35.5 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $25.5 million in Q2 2025 to a low of -$35.5 million in Q4 2025.
• The 4-year median for Free Cash Flow is -$1.3 million (2023), against an average of -$938846.2.
• Across the five-year window, Free Cash Flow soared 1814.15% in 2024 and plunged 11454.74% in 2026, its largest moves.
• Immunocore Holdings' Free Cash Flow stood at -$18.6 million in 2023, then advanced by 5.47% to -$17.5 million in 2024, then plunged by 102.65% to -$35.5 million in 2025, then soared by 56.22% to -$15.6 million in 2026.
• The last three Free Cash Flow figures came in at -$15.6 million (Q1 2026), -$35.5 million (Q4 2025), and -$5.2 million (Q3 2025), per Business Quant data.